期刊文献+

咳嗽变异性哮喘患者诱导痰中嗜酸粒细胞的临床意义 被引量:4

原文传递
导出
摘要 目的探讨咳嗽变异性哮喘患者诱导痰中嗜酸性粒细胞(EOS)与患者肺功能(FEV1%)的相关性以及与接受肾上腺糖皮质激素治疗剂量的相关性。方法选择40例急性加重期咳嗽变异性哮喘的患者,检测其用吸入激素前、治疗1个月后的嗜酸细胞,肺功能(FEV1%)症状严重程度,记录吸入肾上腺糖皮质激素剂量。结果咳嗽变异性哮喘患者痰中嗜酸性粒细胞数与第一秒呼气容积占预计值的百分比(FEV1%)呈负相关(r=-0.691,P〈0.01),与吸入激素量正相关(r=0.821,P〈0.01),患者症状严重程度相关程度正相关(r=0.721,P〈0.01)。结论咳嗽变异性哮喘患者诱导痰中嗜酸性粒细胞计数可作为咳嗽变异性哮喘患者的诊断、严重程度的判定及其吸入肾上腺糖皮质激素剂量的重要参考指标,其简单、可靠、无创、廉价,可在临床上应用。
作者 胡波
出处 《中国综合临床》 2011年第10期1037-1038,共2页 Clinical Medicine of China
  • 相关文献

参考文献8

二级参考文献26

  • 1儿童哮喘诊断标准和治疗常规[J].中华儿童保健杂志,1993,1(4):249-251. 被引量:325
  • 2李凡,蔡映云,王蓓玲.成人哮喘生命质量询问表制定与初步应用分析[J].中国行为医学科学,1995,4(4):193-195. 被引量:21
  • 3中华医学会呼吸病学分会哮喘学组.咳嗽的诊断与治疗指南(草案)[J].中华结核和呼吸杂志,2005,28(11):738-744. 被引量:1461
  • 4[1]Baraldo S,Oliani KL,Turato G,et al.The Role of Lymphocytes in the Pathogenesis of Asthma and COPD[J].Curr Med Chem,2007,14(21):2250-2256.
  • 5[2]Berkman N,Ohnona S,Chung FK,et al.Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge[M].Am J Respir Cell Mol Biol,2001,24(6):682-7.
  • 6[4]Afshar K,Vucinic V,Sharma OP.Eosinophil cell:pray tell us what you do[J].Curr Opin Pulm Med,2007,13(5):414-21.
  • 7[5]Choi KM,Kim JH,Cho GJ,et al.Effect of exercise training on plasma visfatin and eotaxin levels[J].Eur J Endocrinol,2007,157(4):437-42.
  • 8Gibson PG,Powell H.Written action plans for asthma:an evidence based review of the key components.Thorax,2004,59(9):94-99.
  • 9陈春宝 王敏 宋白强.丙卡特罗治疗咳嗽变异哮喘60例临床观察[J].中国基层医药,2009,16(1):52-53.
  • 10Zhong N S,Chest,1992年,102卷,1104页

共引文献214

同被引文献42

  • 1Brightling CE, Symon FA, Birring SS, et al. Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax, 2003,58 (6) :528-532.
  • 2Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity ,2001,15 (6) :985-995.
  • 3Ikeda K, Nakajima H, Suzuki K, et al. Mast cells produce inter- leukin-25 upon Fc epsilon RI-mediated activation. Blood, 2003, 101 (9) :3594-3596.
  • 4Sharkhuu T, Matthaci KI, Forbes E, et al. Mechanism of interleu- kin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity. Clin Exp Allergy,2006,36(12) :1575-1583.
  • 5Angkasekwinai P, Park H, Wang Y, et al. Interleukin-25 promotes the initiation of proalleric type 2 responses. JEM, 2007,204 ( 7 ) : 1509-1517.
  • 6Tamachi T, Maezawa Y, Ikeda K, et al. Interleukin 25 in allergic airway inflammation. Int Arch Allergy Immunal,2006,140 (suppl 1 ) :59-62.
  • 7Ballantyne SJ, Barlow JL, Jolin HE, et al. Blocking IL-25 prevents airway hyper responsiveness in allergic asthma. J Allergy Clin Im- muno1,2007,120(6 ) : 1324-1331.
  • 8施弦,郁峰.诱导痰炎性细胞计数和儿童哮喘严重程度相关性的临床研究[J].中国小儿急救医学,2007,14(6):494-495. 被引量:2
  • 9Mochizuki H,Arakawa H,Tokuyama K. Bronchial sensitivity and bronchial reactivity in children with cough variant asthma[J].Chest,2005,(04):2427-2434.
  • 10Ali Bin Sarwar, Zubairi Nawal, Salahuddin Ali, et al. A random- ized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation [ J ]. BMC pulmonary medicine, 2013, 13:20.

引证文献4

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部